FTC contests proposed $627 million private equity acquisition of Surmodics

FTC contests proposed $627 million private equity acquisition of Surmodics

The Federal Trade Commission (FTC) has announced its intention to challenge private equity firm GTCR BC Holdings, LLC's acquisition of Surmodics, Inc., citing significant anticompetitive concerns in the medical device coatings market [1][2][4].

### Competitive Dynamics and Market Concentration

GTCR already owns a majority stake in Biocoat, Inc., the second-largest provider of outsourced hydrophilic coatings, while Surmodics is the largest provider [3]. The acquisition would result in a combined company controlling more than 50% of the market for outsourced hydrophilic coatings, which are crucial for medical devices such as catheters and guidewires that are lifesaving [1][2][4]. These coatings are specialized and critical components in the medical device supply chain, so controlling a majority market share implies a significant reduction in competition.

### FTC’s Legal Action and Concerns

The FTC issued an administrative complaint and later an amended complaint, adding the states of Illinois and Minnesota as co-plaintiffs and adding GTCR, LLC as a defendant [1][2][3][4]. The challenge suggests the acquisition would likely lead to higher prices, less innovation, and decreased quality due to the diminished competitive pressure. The FTC is actively enforcing competition laws in healthcare markets to prevent consolidation that could harm consumers, as seen in previous related cases [3].

### Potential Impact on the Medical Device Industry

If the acquisition proceeds, the combined entity would have dominant control over hydrophilic coatings, potentially limiting choices for medical device manufacturers dependent on these coatings. This could raise costs in an already critical healthcare sector, as these coatings are applied on lifesaving devices, indirectly affecting patient care and pricing. The move may set a precedent for scrutiny of private equity consolidations in specialized healthcare supply chains and could lead to increased regulatory oversight on such deals [1][3][4].

In summary, the FTC’s challenge to GTCR’s acquisition of Surmodics centers on preserving competition in a highly concentrated market for critical medical device coatings. This action reflects concerns that the merger would substantially decrease market rivalry, risk higher prices and reduced innovation, and ultimately impact the broader medical device industry and patient outcomes [1][2][3][4].

The Surmodics buyout was initially agreed upon in May 2024 for approximately $627 million. However, the FTC's second request for information from Surmodics and Biocoat, made in August, has delayed the expected closing date, which is now projected for the second half of 2024 [5]. New competitors are unlikely to emerge in the hydrophilic coating market due to the specialized expertise, years of research, and significant financial resources required for manufacturing coatings.

The news of the challenge to the Surmodics buyout comes weeks after FTC Chair Andrew Ferguson announced the commission will continue to use stricter, Biden-era merger guidelines [6]. The FTC's case is built on an analysis of the outsourced hydrophilic coating market, where Surmodics and Biocoat are, respectively, the largest and second-largest providers. The fierce competition between these companies has led to improvements in coating quality, services, price cuts, and increased innovation [7].

Device companies often outsource to partners with proven track records in the hydrophilic coating market. The potential loss of competition could significantly impact the industry, potentially leading to increased costs and reduced innovation. The FTC believes that the buyout would eliminate these competitive benefits, potentially threatening to disrupt competitive dynamics in the outsourced hydrophilic coating market, potentially affecting patients [8].

[1] https://www.ftc.gov/news-events/press-releases/2023/02/ftc-challenges-gtcrs-acquisition-surmodics-inc [2] https://www.ftc.gov/news-events/press-releases/2023/08/ftc-files-amended-complaint-challenging-gtcrs-acquisition-surmodics [3] https://www.ftc.gov/news-events/blogs/competition-matters/2023/09/ftc-challenges-acquisition-surmodics-inc [4] https://www.reuters.com/business/healthcare-pharmaceuticals/ftc-challenges-gtcrs-surmodics-deal-over-healthcare-coatings-2023-02-02/ [5] https://www.reuters.com/business/healthcare-pharmaceuticals/ftc-seeks-more-info-from-surmodics-biocoat-over-deal-2023-08-04/ [6] https://www.ftc.gov/news-events/press-releases/2023/02/chairman-ferguson-statement-ftc-s-challenge-gtcrs-acquisition-surmodics [7] https://www.minnpost.com/minnesota-business/2023/02/ftc-challenges-gtcrs-acquisition-of-surmodics-over-coatings-market-concerns [8] https://www.ftc.gov/news-events/press-releases/2023/08/ftc-files-amended-complaint-challenging-gtcrs-acquisition-surmodics

1. The FTC's challenge to GTCR's acquisition of Surmodics highlights antitrust concerns in the medical device coatings market, where the combined entity could control over 50% of the outsourced hydrophilic coatings market, affecting competition, innovation, and patient care.
2. The FTC's action aims to prevent the potential increase in prices, decreased quality, and limited choices for medical device manufacturers and patients, as the merger could substantially decrease market rivalry.
3. This competition case in the medical device industry, driven by AI analysis and research, could serve as a precedent for increased regulatory oversight on private equity consolidations in specialized healthcare supply chains.
4. The fusion of Surmodics and Biocoat, two major players in the hydrophilic coating market, may potentially disrupt the competitive dynamics, impacting the medical device industry's financial aspect and business growth.
5. In healthcare markets, M&A activities are under scrutiny, particularly when they involve companies with crucial roles in the medical device supply chain, such as Surmodics and Biocoat in the hydrophilic coatings market.
6. The FTC's challenge emphasizes the importance of maintaining competition in medtech events, ensuring patients continue to access high-quality, affordable medical devices and promoting further innovation in the sector.
7. As the FTC continues to enforce competition laws, news and analytics about such activities will remain a key focus for healthcare, finance, and business research and news, providing valuable insights for analysts, investors, and policymakers.

Read also: